Cascades Reports Results for the Second Quarter of 2022
Print this Article | Send to Colleague
Cascades Inc. reports its unaudited financial results for the three-month period ended June 30, 2022.
Mario Plourde, President and CEO, commented: "Our packaging businesses delivered good sequential performances in the second quarter, with improved pricing and sales mix, higher volumes, and lower raw material costs in the case of Containerboard outweighing the impact of continued cost inflation. Sequentially, results in our Tissue Papers business highlight the momentum being generated by the profitability initiatives underway. While pricing and mix improvements realized to date helped to mitigate the unprecedented headwinds on the cost side, these initiatives are trailing the pace of the current high inflation environment. These initiatives remain on track to generate important contributions in the back half of 2022, and are being closely monitored and regularly adapted to address the changing cost environment.
We continued to advance the Bear Island project in the quarter. The capital investments for this project, which totaled $81 million in the second quarter and $145 million year-to-date, combined with lower consolidated financial results, has resulted in an increase in our leverage in the second quarter. As we have previously stated, this trend is expected to reverse with improved business performance through the remainder of 2022 and throughout 2023 as well as the positive contribution from this facility following its start-up."
Near-Term Outlook
Discussing near-term outlook, Mr. Plourde commented, "We are focused on driving benefits from profitability initiatives underway in our Tissue Papers segment. While the level of expected long-term financial contributions remains intact, persistent cost headwinds and adjustments to the implementation timing of announced industry price increases have reduced our forecasted OIBD range for this segment to $25 - $40 million for 2022, from the previously stated $60 - $80 million2. This revision does not change the 2024 OIBD targets provided in our strategic plan in February. "The current inflationary environment has also had implications for our Bear Island project in 2022. Higher cost levels combined with labour and material availability constraints, which have led to temporary delays in certain construction milestones, increased the total projected cost for this project to a range of $595 - $615 million (US$470 - US$485 million). Our team is working closely with contractors to mitigate any potential delay caused by these elements in order to meet the targeted mid-December 2022 start date. However, it is important to note that the timing of some critical construction milestones may be at risk due to these issues and, as a result the start-up of paper production may be delayed to the first quarter of 2023.
"At the operations level, we are forecasting sequentially stable results in our packaging businesses in the third quarter, during which favourable pricing momentum is expected to mitigate continued cost inflation. As we have previously stated, the Tissue Papers business is expected to return to a trajectory of positive contribution in the upcoming quarters as meaningful benefits from implementation of the profitability initiatives begin to be realized."
Analysis of results for the three-month period ended June 30, 2022 (compared to the same period last year)
Sales of $1,119 million increased by $163 million compared with the same period last year. This reflects $146 million of combined benefits from improvements in selling prices and sales mix in all business segments. The Canadian dollar - US dollar exchange rate was also favourable for all businesses, contributing $24 million to sales levels on a consolidated basis. These were partially offset by a $16 million impact related to lower volumes in the Containerboard and Tissue Papers business segments.
The Corporation generated an operating income before depreciation and amortization (OIBD) of $95 million in the second quarter of 2022, up from $87 million in the second quarter of 2021. On an adjusted basis1, second quarter OIBD totaled $91 million, a decrease of $7 million, or 7% from the $98 million generated in the same period last year. This decrease is attributable to higher raw material, production, energy and logistics costs in all segments, the effects of which were not fully mitigated by improvements in selling prices and mix in all businesses and a beneficial FX impact for the packaging segments.
The main specific items, before income taxes, that impacted our second quarter 2022 OIBD and/or net earnings were:
• $4 million gain from the settlement of a supply agreement in Tissue Papers segment (OIBD and net earnings);
• $3 million foreign exchange loss on long-term debt and financial instruments (net earnings).
For the 3-month period ended June 30, 2022, the Corporation posted net earnings of $10 million, or $0.10 per common share, compared to net earnings of $3 million, or $0.02 per common share, in the same period of 2021. On an adjusted basis, the Corporation generated net earnings of $10 million in the second quarter of 2022, or $0.10 per common share, compared to net earnings of $8 million, or $0.07 per common share, in the same period of 2021.
